Obsessive-Compulsive Disorder

Clinical picture

• Obsessions are intrusive, unwanted, and ego-dystonic; patients recognize them as their own thoughts yet experience them as senseless and repugnant.
• Common symptom dimensions include contamination and washing, harm and checking, symmetry and ordering, and taboo sexual, religious, or aggressive themes.
• Compulsions are rule-bound rituals, overt or mental, performed to neutralize distress or prevent a feared outcome, with only transient relief.
• Patients often conceal taboo obsessions for years, and the average delay from symptom onset to adequate treatment approaches a decade.
• Reassurance seeking, family accommodation, and avoidance sustain the cycle and are the most common reasons an otherwise sound treatment stalls.
• Insight ranges from good to absent or delusional; poor insight predicts greater severity, more accommodation, and weaker treatment response.

Criteria snapshot

• Requires obsessions, compulsions, or both, defined by intrusive repetitive thoughts and by repetitive behaviors or mental acts aimed at reducing distress.
• Symptoms must be time consuming, generally exceeding one hour per day, or must cause marked distress or clear functional impairment.
• Not attributable to a substance, medication, or another medical condition, and not better explained by another mental disorder's content.
• Specify insight as good or fair, poor, or absent and delusional, and specify whether tic-related, which shapes augmentation choices.
• Hoarding, body-focused repetitive behaviors, and appearance preoccupations are coded as separate related disorders rather than as OCD.

Neurobiology

• Hyperactivity in the cortico-striato-thalamo-cortical loop, especially orbitofrontal cortex, anterior cingulate, and caudate, normalizes with successful treatment.
• Serotonergic modulation is central; response requires higher SSRI doses and 10-12 weeks, implicating downstream receptor adaptation rather than acute reuptake block.
• Glutamatergic excess in striatal and cingulate regions supports augmentation trials of memantine, riluzole, and N-acetylcysteine in resistant cases.
• Twin heritability is roughly 40-50% in adults and higher in pediatric-onset illness; SLC1A1 and glutamate-pathway variants are the most replicated signals.
• Dopaminergic striatal involvement helps explain the efficacy of low-dose antipsychotic augmentation, particularly in tic-related presentations.
• Abrupt pediatric onset with tics, restricted eating, and emotional lability raises suspicion for PANS or PANDAS and warrants targeted infectious workup.

Psychology

• Cognitive model holds that intrusions are universal and pathology arises from catastrophic misappraisal of their meaning and an inflated sense of responsibility.
• Thought-action fusion, intolerance of uncertainty, and perfectionism convert ordinary doubt into an unending and unmeetable demand for certainty.
• Compulsions are negatively reinforced by immediate anxiety reduction, which prevents disconfirmation of feared outcomes and strengthens the loop.
• Family accommodation, present in most households, predicts poorer outcome and must be measured directly and targeted as a treatment goal.
• Mental rituals, covert neutralizing, and reassurance seeking masquerade as ordinary thinking and are routinely missed on standard screening questions.

Differential & comorbidity

• Distinguish from generalized anxiety, where worries concern realistic life domains, and from psychosis, where beliefs are not experienced as ego-dystonic.
• Body dysmorphic disorder, hoarding, illness anxiety, and eating disorders share ritual structure but differ in the content that drives the behavior.
• Lifetime comorbidity is high: major depression in up to 40%, other anxiety disorders, and tic disorders in roughly 30% of pediatric cases.
• Suicidal ideation occurs in about a quarter of patients and tracks with depression severity and taboo obsessions; screen at every visit.
• Screen for autism spectrum traits and OCPD, where rigid routines and perfectionism are ego-syntonic rather than distressing and resisted.

Pharmacologic treatment

• First-line SSRIs at high doses: fluoxetine 40-80 mg/day, sertraline 100-200 mg/day, or escitalopram 20-30 mg/day as tolerated.
• Allow 10-12 weeks at the maximal tolerated dose before declaring nonresponse; expect 40-60% response with 25-35% symptom reduction.
• Clomipramine 150-250 mg/day remains the most potent agent; monitor ECG, anticholinergic burden, and seizure risk above 250 mg/day.
• Augment partial responders with low-dose aripiprazole 5-15 mg/day or risperidone 0.5-3 mg/day, most useful in tic-related OCD.
• Continue treatment at least 1-2 years after remission and taper slowly; relapse exceeds 50% after abrupt discontinuation.

Psychotherapy

• Exposure and response prevention is first-line, typically 12-20 sessions combining therapist-guided exposures with daily self-directed practice.
• ERP effect sizes exceed medication monotherapy, and adding ERP to an SSRI outperforms medication alone in moderate to severe illness.
• Cognitive therapy targeting inflated responsibility, thought-action fusion, and intolerance of uncertainty is effective when ERP is refused.
• Acceptance and commitment therapy and inhibitory-learning exposure improve engagement for patients unwilling to tolerate a habituation framing.
• Family-based ERP is the standard for children and adolescents and explicitly targets reduction of parental accommodation.

Adjunct options

• Track severity with the Y-BOCS or CY-BOCS at baseline and every 4-6 weeks; a 35% score reduction defines treatment response.
• Intensive outpatient, partial hospitalization, and residential OCD programs benefit patients who fail two adequate outpatient medication trials.
• Deep TMS targeting medial prefrontal and anterior cingulate cortex is FDA-cleared as an adjunct for treatment-resistant adult OCD.
• Deep brain stimulation of the ventral capsule and ventral striatum carries an FDA humanitarian device exemption for severe refractory illness.
• Sleep regulation, aerobic exercise, and abstinence from alcohol and cannabis reduce symptom amplification and improve exposure tolerance.

Clinical pearls

• OCD needs higher SSRI doses and longer trials than depression: 10-12 weeks before calling it a failure.
• Ask directly about mental rituals and reassurance seeking; patients rarely volunteer either one.
• Cutting family accommodation often moves severity more than another dose increase.